Login to Your Account

Other News To Note

Wednesday, August 15, 2012
• Arrowhead Research Corp., of Pasadena, Calif., said that it entered into an agreement with Merck & Co. Inc., through a subsidiary, to evaluate a novel therapeutic monoclonal antibody candidate derived from its human-derived peptide targeting and discovery program, which was acquired through the purchase of Alvos Therapeutics in April.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription